# Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

> **NCT03161041** · PHASE2 · WITHDRAWN · sponsor: **Hospices Civils de Lyon**

## Conditions studied

- Colorectal Carcinomatosis

## Interventions

- **PROCEDURE:** Cytoreductive surgery combined with HIPEC
- **DRUG:** bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).

## Key facts

- **NCT ID:** NCT03161041
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-21
- **Primary completion:** 2018-11-13
- **Final completion:** 2018-11-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** CHU Lyon will join as a participating center (and as national French coordinator) as a part of the BEV-IP study ongoing study EudraCT-number 2014-004257-14.
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161041, "Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03161041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*